• Efficient iPSC-to-Retinal Ganglion Cell Differentiation via

  2026-05-26

  The reference study establishes a reproducible, chemically defined protocol for differentiating human induced pluripotent stem cells into retinal ganglion cells (RGCs) through dual SMAD and Wnt pathway inhibition. This innovation markedly improves RGC yield and experimental consistency, offering a robust platform for glaucoma and neurodegenerative disease research.

• hiPSC-Derived Intestinal Organoids Advance CYP2C19 Drug Meta

  2026-05-25

  This study presents a direct 3D culture protocol for generating human induced pluripotent stem cell (hiPSC)-derived intestinal organoids, offering a tractable and physiologically relevant platform for in vitro pharmacokinetic studies. The approach overcomes limitations of animal models and conventional cell lines, enabling precise evaluation of CYP2C19 substrate metabolism and drug absorption relevant to human physiology.

• Toremifene Citrate in Breast Cancer Research: Reliable Proto

  2026-05-25

  Toremifene Citrate (SKU B1513) is an oral selective estrogen receptor modulator widely utilized in breast cancer and endocrinology research. This article addresses five real-world laboratory scenarios, demonstrating how Toremifene Citrate supports reproducible, data-driven results, and highlighting APExBIO's role in providing high-quality, research-grade reagents for hormone receptor modulation.

• Serotonin Receptor Modulators Influence Olaparib Resistance

  2026-05-24

  This study leveraged high-throughput screening of an FDA-approved compound library to identify serotonin receptor modulators as regulators of olaparib resistance in ovarian cancer cells. The findings reveal complex and context-dependent modulatory effects, highlighting new directions for understanding chemoresistance mechanisms.

• IWP-L6: Precision Porcupine Inhibitor for Wnt Pathway Contro

  2026-05-23

  IWP-L6 offers sub-nanomolar Porcupine inhibition for robust, reproducible Wnt pathway modulation in advanced cell, organoid, and in vivo models. This guide delivers actionable workflow enhancements, troubleshooting strategies, and practical insights drawing from the latest metabolic and developmental research.

• DiscoveryProbe FDA-approved Drug Library for Targeted Screen

  2026-05-22

  Unlock translational breakthroughs in drug repositioning and target identification with the DiscoveryProbe™ FDA-approved Drug Library. This rigorously curated, ready-to-screen compound collection accelerates high-throughput workflows and empowers researchers to tackle unmet biomedical challenges with maximal efficiency and reliability.

• Molidustat (BAY85-3934): Precision in HIF Stabilization for

  2026-05-22

  Explore the scientific depth of Molidustat (BAY85-3934) as a novel HIF-PH inhibitor for renal anemia therapy. This article uniquely analyzes its molecular mechanism, translational applications, and reference-driven insights for advanced assay design.

• Strategic Lysosome Imaging: From Mechanism to Translation

  2026-05-21

  This thought-leadership article unpacks the mechanistic, experimental, and strategic imperatives of lysosome labeling in live cells, spotlighting Lyso-Tracker Red and its pivotal role in advancing translational research. By integrating recent mechanistic breakthroughs in renal cancer therapy with best-practice protocols and competitive landscape analysis, we provide actionable guidance for researchers seeking to harness lysosomal biology for disease modeling and therapy innovation.

• Humanized Mouse Models Reveal CES Prodrug HD56’s Translation

  2026-05-21

  This study demonstrates that humanized mice provide a high-fidelity in vivo model for assessing species-specific pharmacokinetics and in vivo-in vitro correlation (IVIVC) of carboxylesterase-activated prodrugs such as HD56. The findings highlight the necessity of humanized models for accurate preclinical development of ester prodrugs and offer methodological frameworks transferable to other drug classes, including influenza neuraminidase inhibitors.

• Indazole-Based Glucagon Receptor Antagonists: Synthesis and

  2026-05-20

  This article reviews the discovery and development of a novel series of indazole-/indole-based glucagon receptor antagonists targeting Type 2 Diabetes Mellitus (T2DM). The work highlights innovative synthetic strategies—particularly in amide bond formation—and discusses their pharmacological profiles, emphasizing both the methodological advances and translational relevance.

• WY-14643 (Pirinixic Acid): Transforming Metabolic Disorder R

  2026-05-20

  WY-14643 (Pirinixic Acid) stands out as a potent, selective PPARα agonist, driving advances in lipid metabolism and anti-inflammatory research. With proven efficacy in both metabolic and tumor microenvironment studies, this APExBIO reagent unlocks reproducible workflows for translational investigators tackling complex disease models.

• High-Dose Maternal Tamoxifen Induces Mouse Fetal Malformatio

  2026-05-19

  The referenced study demonstrates that a single high dose of tamoxifen in pregnant mice results in dose-dependent craniofacial and limb malformations in developing embryos. These findings highlight the importance of careful dosing and timing when using tamoxifen as a selective estrogen receptor modulator in genetic models, especially for CreER-mediated applications.

• High-Dose Maternal Tamoxifen Induces Developmental Malformat

  2026-05-19

  This study demonstrates that a single high dose of tamoxifen administered to pregnant mice at a critical gestational stage leads to consistent limb and craniofacial malformations in offspring. The findings highlight the need for careful dosing and timing in experimental designs employing tamoxifen-inducible gene knockout systems.

• GPR35-KLF5 Signaling Orchestrates Epithelial Repair in Colit

  2026-05-18

  This study elucidates a metabolic signaling circuit in which GPR35 senses tryptophan metabolite cues, activating KLF5-driven repair programming in intestinal epithelial cells. The findings clarify how mucosal damage signals are decoded for effective repair, shaping future ulcerative colitis research and model optimization.

• Tamoxifen: Mechanisms, Protocols, and Limits in Research Use

  2026-05-18

  Tamoxifen, a selective estrogen receptor modulator, is widely used in breast cancer research and gene knockout models. Its dual antagonistic and agonistic effects make it uniquely valuable, but its use requires careful protocol design and awareness of solubility and off-target actions.

462 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page